- Home
- POLE vs VNDA Comparison
POLE vs VNDA Comparison
Compare POLE & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POLE
- VNDA
- Stock Information
- Founded
- POLE 2024
- VNDA 2002
- Country
- POLE United States
- VNDA United States
- Employees
- POLE N/A
- VNDA N/A
- Industry
- POLE
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- POLE
- VNDA Health Care
- Exchange
- POLE NYSE
- VNDA Nasdaq
- Market Cap
- POLE 296.0M
- VNDA 257.8M
- IPO Year
- POLE 2024
- VNDA 2006
- Fundamental
- Price
- POLE $10.08
- VNDA $4.43
- Analyst Decision
- POLE
- VNDA Strong Buy
- Analyst Count
- POLE 0
- VNDA 2
- Target Price
- POLE N/A
- VNDA $16.50
- AVG Volume (30 Days)
- POLE 3.6K
- VNDA 649.7K
- Earning Date
- POLE 01-01-0001
- VNDA 02-13-2025
- Dividend Yield
- POLE N/A
- VNDA N/A
- EPS Growth
- POLE N/A
- VNDA N/A
- EPS
- POLE N/A
- VNDA N/A
- Revenue
- POLE N/A
- VNDA $198,772,000.00
- Revenue This Year
- POLE N/A
- VNDA $16.07
- Revenue Next Year
- POLE N/A
- VNDA $24.42
- P/E Ratio
- POLE N/A
- VNDA N/A
- Revenue Growth
- POLE N/A
- VNDA 3.18
- 52 Week Low
- POLE $9.94
- VNDA $3.71
- 52 Week High
- POLE $11.05
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- POLE N/A
- VNDA 44.53
- Support Level
- POLE N/A
- VNDA $4.34
- Resistance Level
- POLE N/A
- VNDA $4.65
- Average True Range (ATR)
- POLE 0.00
- VNDA 0.21
- MACD
- POLE 0.00
- VNDA -0.01
- Stochastic Oscillator
- POLE 0.00
- VNDA 36.51
About POLE ANDRETTI ACQUISITION CORP. II
Andretti Acquisition Corp II is a blank check company.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.